israeli life science company catalog · 2015-07-13 · prior to 1996, israel was home to 186 life...
TRANSCRIPT
Israeli Life Science Company Catalog Tokyo, Japan | 28-30 July 2015
1 | P a g e
2 | P a g e
Meet the 2015 Israeli Life Sciences Delegation to Japan
On behalf of the organizers and partners, we would like to introduce you to the 2015 Israeli
Life Science Delegation to Japan. The delegation of 12 innovative life science companies
represents a wide spectrum of Israel’s vigorous life science community, from innovative start-
ups to established companies in the fields of pharma, medical devices, health IT and more.
Please take the time to explore their innovative solutions in this catalog, and meet the
companies at a special cooperation seminar on July 30, 2015 at the Inno Hall & Convention
Center in Tokyo.
Why Israel?
Over the last decade, Israel has introduced a wealth
of groundbreaking and valuable innovations in life
sciences. Israel’s life sciences sector is supported by
a strong foundation of academic excellence,
including some of the world’s leading research
institutes, renowned R&D facilities and cutting-
edge medical centers. Bolstered by a highly skilled
workforce, a flourishing high-tech environment,
and an entrepreneurial spirit, Israeli companies
have been joined by leading multinationals in
making Israel a recognized force in the industry
worldwide.
Prior to 1996, Israel was home to 186 life sciences
companies. By 2014, this number had passed 1,300.
With some 70 new companies formed each year,
66% of all life sciences companies operating in
Israel today were established during the last ten
years. In a relatively short period of time, an
impressive 34% of these companies have already
begun to generate revenue, demonstrating that
Israel has crossed the threshold from an attractive
start-up arena to a source of advanced,
commercially viable and promising businesses. The
bridge connecting excellent science to revenue-
generating companies has been established. As
proof of the industry’s development, in 2014 life
sciences exports reached $8.5 billion, an increase of
10% over 2010. A rich pipeline of seed companies
promises to perpetuate current growth.
Over 1000 life sciences companies
Over 1/3 of LS Start-Ups already generate revenue
Source of numerous blockbuster drugs such as Copaxone and Rebif, generating over $5B in annual sales
First in the world in quality of scientific research institutions
First in the world for medical
device patents per capita, 2th for bio-pharma (US Patent Office 2011)
Pioneers in stem cell research and
therapeutics
Extensive international R&D and commercial partnerships
World-renowned academic
research institutes such as the Technion and Weizmann Institute
3 | P a g e
Meet the Sponsoring Organizations
The sponsoring organizations of the Israeli delegation provide a full array of support and services
to nurture the development of industry and innovation:
The Ministry of Economy, Trade and Industry or METI, is a ministry of the
Government of Japan. It was created by the 2001 Central Government
Reform when the Ministry of International Trade and Industry merged with
agencies from other ministries related to economic activities, such as the
Economic Planning Agency. METI is organized into the following bureaus,
offices, departments and 4 agencies (Agency for Natural Resources and
Energy, Nuclear and Industrial Safety Agency, Small and Medium
Enterprise Agency, Japan Patent Office).
Following its establishment in 1980, the New Energy and Industrial
Technology Development Organization (NEDO) has become Japan's
largest public research and development management organization. In
this role NEDO undertakes technology development and demonstration
activities to carry out two basic missions, addressing energy and global
environmental issues and enhancing industrial technology, by integrating
the combined efforts of industry, academia and government.
The Office of the Chief Scientist (OCS) in the Ministry of Economy is
charged with execution of government policy for support of industrial
R&D. The OCS assists in the development of technology in Israel as a
means of fostering economic growth, encouraging technological
innovation and entrepreneurship, leveraging Israel’s scientific potential,
and encouraging R&D collaboration both nationally and internationally.
MATIMOP, the executive agency of the Office of the Chief Scientist (OCS)
of the Israeli Ministry of Economy, promotes industrial R&D cooperation
between Israeli and foreign companies through partner-matching and
access to funding. MATIMOP is charged with promoting highly supportive
policies to nurture industrial innovation and entrepreneurship.
The Foreign Trade Administration at the Ministry of Economy is
responsible for managing and directing the international trade policy of
the State of Israel. The main fields of activity include activities for the
promotion of trade and export, initiating and maintaining trade
agreements for the improvement of Israel’s trade conditions, attracting
and encouraging foreign investments and creating strategic cooperation
with foreign companies.
4 | P a g e
The Japan-Israel R&D Cooperation Program
In July 2014, METI and the Israeli Ministry of Economy (MOE) signed a landmark agreement
(MOC) to support industrial R&D cooperation between Japan and Israel. The Memorandum of
Cooperation (MOC) aims at encouraging industrial R&D cooperation and increased business
ties between private sector firms from Japan and Israel. Together with a complimentary
agreement signed between the ministries’ implementation bodies – MATIMOP and NEDO –
this agreement serves as a basis for the new Japan-Israel R&D Cooperation program. Under
the program, Israeli and Japanese companies have access to government funding for
collaborative R&D projects as well as assistance in locating R&D and business partners.
Companies of all sizes from Japan and Israel are invited to partner up and – during the
program’s “calls for proposals” - apply for funding for joint R&D projects aimed at the
development of innovative new technologies or processes leading to commercialization in the
global market.
We encourage you to browse the catalog and identify and reach out to potential partners. In
addition to this resource, MATIMOP and NEDO are available to conduct dedicated partner
searches for both Israeli and Japanese companies based on their individual needs and
requirements. Just contact a MATIMOP or NEDO representative to start the process.
www.nedo.go.jp/
www.matimop.org.il/japan.html
5 | P a g e
Company Short Description Page
An innovative company that manufactures and sells a
variety of products and services related to dental
implants and prosthetic parts
7
Advanced clinical stage drug development company with
a platform technology that addresses multi-billion dollar
markets in the treatment of cancer, autoimmune
inflammatory diseases and sexual dysfunction.
8
DermaCompare is a revolutionary skin cancer screening
platform that enables physicians to identify and monitor
changes in their patients' skin characteristics.
9
EyeYon Medical is developing an innovative, patent
protected technology that has proved the feasibility to
cure an acute problem in ophthalmology.
10
Kamada is a NASDAQ traded fully integrated
biopharmaceutical company, focused on therapeutics for
orphan indications. The company has a wide commercial
product portfolio and a robust late-stage clinical pipeline.
11
Moebius Medical Ltd. is an innovative clinical stage
biotechnology company that is developing a proprietary
treatment for Osteoarthritis.
12
NeviMed has developed the DermoScout, a Full Body
Skin Scanner (dermatology health booth), for monitoring
a wide variety of abnormal skin conditions. 13
6 | P a g e
NovellusDx is a Molecular Personalized Medicine
company dedicated to delivering the actionable
intelligence that oncologists require in order to choose
the right therapy for each patient. 14
The Process is the Product: Pluristem a leader in cell
therapy.
16
PolyPid is a clinical stage, emerging specialty
pharmaceutical company developing, manufacturing and
eventually commercializing products based on our
proprietary PLEX™ (Polymer-Lipid Encapsulation matriX)
platform in the field of extended release, local drug
delivery.
17
A medical device manufacturer specializing in laser
cutting, micromachining and finishing of miniature metal
components. 18
TechsoMed is an Israeli based medical device company,
developing ultrasound based real-time monitoring
systems for thermal ablation procedures. 19
TransAlgae develops algae based platform for oral
delivery (replacing injections) of proteins based drugs
and other bio-molecules for the animal healthcare, crop
protection and human pharma fields. 20
7 | P a g e
AB Dental Devices Ltd.
Technology Sector: Medical Devices
Technology Subsector: Dental
Website: www.ab-dent.com
Company Description:
A.B. Dental is a dynamic and innovative service-based company providing the dentist a
complete solution, which includes computerized implant planning and custom individual
implants using laser-sintering technology. With top-of-the-line technology and extensive
industry experience, we specialize in the development, manufacturing and marketing of dental
implants, prosthetic products and surgical tools.
Computerized implant planning
3D printing of surgical guides
Custom individual implants using laser-sintering technology
A wide range of implants, prosthetic products, tools, accessories and CAD/CAM solutions
required for the dentist to perform an accurate and successful treatment
In-house training center fully equipped for lectures and hands-on training.
Partnership Interests:
AB Dental is looking for several avenues of cooperation in Japan: (1) Identifying Distribution
channels on nationwide basis; (2) Identifying R&D partners for future research in Japan both in
the industrial sector as well as the academic sector (3) Cooperation with Government
institutes/municipalities on both commercial basis as well as academic
Eric Ben Mayor Vice President of
Business Development [email protected]
8 | P a g e
Can-Fite BioPharma
Technology Sector: Biotech
Technology Subsector: Drug Development
Company Stage: Public Company: NYSE MKT: CANF;
TASE: CFBI
Website: www.canfite.com
Company Description:
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) is an advanced clinical stage drug development
company with a platform technology that addresses multi-billion dollar markets in the treatment
of cancer, inflammatory diseases, and sexual dysfunction. The Company's CF101 drug
candidate is currently under advanced clinical development, preparing to enter Phase III and
Phase II/III trials for two indications, Rheumatoid Arthritis and Psoriasis. Can-Fite's liver cancer
drug CF102 is in Phase II trials for patients with advanced disease. CF102 has been granted
Orphan Drug Designation by the U.S. Food and Drug Administration and is approved for
Compassionate Use by Israel's Ministry of Health. Can-Fite's 3rd drug candidate, CF602, has
shown efficacy in the treatment of erectile dysfunction in preclinical studies. The Company's
drug candidates have an excellent safety profile with experience in over 1,200 patients in
clinical studies to date. Can-Fite's intellectual property portfolio consists of 120 patents issued
and pending.
Partnership Interests:
Out-
licen
sing
our
drug
cand
idat
es.
Dr. Sari Fishman Director of Business
Development [email protected]
Dr. Adi Zamir VP Product & Operations
9 | P a g e
Emerald Medical
Technology Sector: Life Sciences
Technology Subsector: Healthcare IT
Company Stage: R&D
Website: www.dermacompare.com
Company Description:
Emerald is digital health startup company engaged in the development, sale and service of
imaging solutions utilizing. DermaCompare is Emerald's first application of its technology, which
we hope will represent an advance in the world of dermatology and aid the early detection of
skin cancer. DermaCompare utilized the knowledge learned from advanced military image
processing and data analytics to improve the analysis of medical images for the benefit of
patients and the medical community. DermaCompare is a revolutionary Total Body Photography
(TBP) melanoma-screening platform that enables physicians to identify and monitor changes in
their patients' skin characteristics. Using Big Data and a multi-dimensional database,
DermaCompare utilizes crowd–sourced data that serves as a decision support platform for
early-stage diagnosis of skin cancer.
DermaCompare's revolutionary system allows dermatologists and other medical care
professionals, using a set of 25 total body photography ("TBP"), to capture sets of skin lesion
images with, among other devices, digital cameras, camera-equipped smartphones or tablets.
These images are then transmitted online and are remotely analyzed by professionals using our
DermaCompare software. DermaCompare has 2 main modules: a SaaS cloud-based "Dr.
Module" that can be launched on any desktop computer connected to the Internet, and a
Mobile APP for mass population uses can be installed on
smart phones or tablets with iOS or Android.
DermaCompare’s intelligent platform enables physicians
to provide a faster, more accurate and improved
diagnostics service for their patients from the very first
checkup, with access to the world’s first crowd sourced
big multidimensional dermatological database.
our solution to skin cancer, can be easily customized to other skin issues like tracking treatment
to acne, wrinkles or skin diseases, and on the other hand to breast cancer - by comparing
memography images. We would like to cooperate to promote our new development directions,
based on our current solution and technology.
10 | P a g e
EyeYon Medical
Technology Sector: Medical Devices
Technology Subsector: Ophthalmic medical devices
Company Stage: Initial Revenues
Website: www.eye-yon.com
Company Description:
EyeYon Medical is specializing in developing medical ophthalmic devices, which offer unique
solutions for a phenomenon resulting from corneal edema. EyeYon Medical has promising,
exclusive technologies that have proven the feasibility of a solution to an acute problem in the
ophthalmic world.
EyeYon Medical has two innovative, patent-protected technologies, which are in the research
and development stage:
1. Hyper CLTM -Hyperosmotic contact lens—a unique contact lens that creates a cavity
above the center of the cornea. That cavity can store hypertonic drops for long duration
and by that, extract fluids by osmosis from the cornea. The Hyper CLTM has shown
impressive capabilities for the relief of corneal edema in extensive clinical trials. The
unique design of the lens found to be beneficial for a variety of indications that are now
being tested. The Hyper CLTM is CE approved and in commercialization stage.
2. DSPEK - Descemet’s Stripping Pseudo Endothelial Keratoplasty — offers a solution by an
implant in the form of a silicon film attached to the posterior corneal surface, thereby
resolving the “root” of the problem. The implantation of the silicon layer will prevent
transfer of fluids into the cornea and thereby avoid the creation of edema in the ailing eye.
The DSPEK proofed feasibility in preclinical trials.
Partnership Interests:
Distributors and market leaders (ophthalmology)
Manufacturing in Japan.
Strategic partnerships.
Nahum Ferera CEO
11 | P a g e
Kamada Ltd.
Technology Sector: Healthcare
Technology Subsector: Pharmaceuticals
Company Stage: Revenue Growth
Website: www.kamada.com
Company Description:
Kamada is an Israeli-based, NASDAQ traded fully integrated biopharmaceutical company,
focused on plasma-derived protein therapeutics for orphan indications. The company has a
wide commercial product portfolio with 10 marketed products in more than 15 countries, and a
robust late-stage clinical pipeline.
Kamada's flagship product is GLASSIA®, a best-in-class, FDA- approved treatment, for alpha-1
antitrypsin deficiency (AATD). The company has strategic agreements with leading companies
such as Baxter, Chiesi, Kedrion, PARI, Biotest, etc.
Kamada has five late-stage plasma-derived protein products in development, including a novel
inhaled formulation of AAT for the treatment of AAT deficiency which completed pivotal Phase
2/3 clinical trial in Europe, and additional high value orphan indications for AAT, including Graft
vs. Host Disease (GvHD), Lung Transplantation and Type-1 Diabetes (T1D).
In addition, Kamada completed enrollment in its U.S. Phase 2/3 of KamRAB® - a post-exposure
prophylaxis for rabies.
Partnership Interests:
Kamada has a broad clinical development plan for its Alpha-1 Antitrypsin for new indications.
The company is now involved in several clinical trials in Israel and the USA among which Graft
Versus Host Disease (GvHD) and Lung Transplantation. We seek for a local Japanese
partner to commercialize the product for these indications.
In addition, Kamada is seeking for in-licensing opportunities and wishes to find a partner to
commercialize its anti-rabies product in Japan.
Roee Nir Business Development
Manager [email protected]
12 | P a g e
Moebius Medical Ltd.
Technology Sector: Orthopedics / Rheumatology
Technology Subsector: Osteoarthritis (OA)
Website: www.moebiusmedical.com
Company Description: Moebius Medical is developing MM-II, a novel liposome-based bio-
lubricant for long-term treatment of osteoarthritis. Based on the clinical data from its completed
clinical study, MM-II shows significant promise as the next generation intra-articular treatment
for OA. MM-II`s success is due to its unique composition of liposomes, which act as "biological
ball bearings". Its structure and superior mechanical lubrication properties facilitate cartilage
surface gliding, thus preventing further wear and friction, as well as subsequent joint damage.
Backed by an aging population, the market for OA treatment in Japan has grown steadily over
the last 30 years, and is expected to continue growing for the foreseeable future. OA is a
disease of the entire joint and there is currently no cure. Treatments focus on relieving
symptoms and improving function, and can include a combination of patient education, physical
therapy, weight control, medication and eventually total joint replacement. It is estimated that
25M people above 40 years of age are affected by knee OA in Japan. The market for hyaluronic
acid (the standard of care for OA) is approximately $900M in the USA and $700M annually in
Japan, even though only 7-9% of knee OA pain sufferers are being treated with HA.
Moebius Medical has successfully completed a randomized, double-blind clinical trial at
Hadassah Medical Center, showing the superiority of treatment with MM-II as compared with
the standard intra-articular treatment (hyaluronic acid).
Advantages/Features of MM-II: Prolonged therapeutic effect as compared with existing
solutions Prevents further cartilage friction and wear Comprised of safe and approved
compounds Being better than the standard of care, MM-II has the potential to take a larger
market share.
Partnership Interests: Moebius is seeking to partner with a Japanese company for the
development and commercialization of the MM-II product by way of licensing, collaboration,
collaborative venture, or receiving an equity investment.
Dr. Yaniv Dolev CEO
13 | P a g e
NeviMed Ltd.
Technology Sector: Medical Devices
Technology Subsector: Dermatology,
Plastic surgery - Tele-health, eHealth, Diagnosing, Monitoring
Company Stage: R&D
Website: www.NeviMed.com
Company Description:
Melanoma cancer is a widespread disease that mainly attacks the Caucasians ethnic group. While melanoma is uncommon in African, Latinos, and Asians, it is frequently more fatal for those populations. About 85% of the ¼ billion new annual cases, occur in developed countries and result in high mortality rates; roughly 10,000 annually in the US alone. Early diagnosis increases the 5 year survival prognosis from 16% to above 98%. Dermatologists currently perform lengthy manual examinations in a small minority of the population-at-risk, and they encounter a relatively high rate of false negatives.
NeviMed has developed the DermoScout, a Full Body Skin Scanner (dermatology health booth),
for monitoring a wide variety of abnormal skin conditions. DermoScout is equipped with
advanced algorithms capable of comparing, tracking, screening and diagnosing multiple
phenomena.
The first generation DermoScout, in addition to providing remote examination capabilities, will utilize algorithms focused on Melanoma screening. DermoScout will assist the dermatologist with a patients’ examination, and will decrease false negatives and reduce the physician’s time per patient from 30-50 minutes to less than 6 minutes. This will enable the dermatologist to significantly increase revenues per patient, and increase the total clientele and the derived revenues.
Partnership Interests:
NeviMed is seeking:
Investments
Design of the scanner hardware (Imaging device, robot)
Manufacturing capabilities
Marketing and Sales opportunities
Uri Shkolnik CEO
14 | P a g e
NovellusDx
Technology Sector: Personalized Medicine (Cancer)
Technology Subsector: Molecular Biology
Company Stage: R&D (Starting servicing pharma & Patients early 2016)
Website: www.novellusdx.com
Company Description:
NovellusDx is a Molecular Diagnostics company dedicated to delivering the actionable
intelligence that oncologists require in order to choose the right therapy for each
patient. NovellusDx provides comprehensive oncogenic activity profiling of individual patient
tumors including charting the full landscape of known and unknown mutations that drive
cancer’s progression, as well as the hierarchy of driver mutations and mutation Cross-Talk. By
measuring the activity of signaling pathways within a tumor, NovellusDx’s Precision Cancer
Analysis™ System can assess the oncogenic activity of mutations and their response to targeted
drugs for every patient individually. In addition, the Precision Cancer Analysis™ System helps
biopharma companies identify expanded subgroups of cancer patients who are likely to respond
to existing therapies, stratify patients to enable more focused and efficient trials and isolate
new mutations to target. NovellusDx has analyzed dozens of human case studies that
demonstrate the actionable information our system provides well beyond that provided by NGS.
NovellusDx technology offers solutions for two markets:
1. Patient-oriented precision medicine: NovellusDx addresses two major bottlenecks that limit
the ultimate utilization of Next Generation Sequencing (NGS) patient data:
a. NovellusDx technology discriminates between passenger mutations and driver mutations.
Supporting the physicians with the actionable report for better clinical decision.
b. NovellusDx test relevant targeted therapeutics drugs and drugs combination on the
patient emulated tumor and detect the drug or combination of drugs to inhibit patient
activated signaling best.
2. Drug discovery: NovellusDx is solving several tailbacks -
a. Better patient selection in clinical trials.
b. Estimate the need for companion diagnostics for a given drug and better support it.
c. Help identify the pathway inhibited by a given drug to expand the use of compounds.
Partnership Interests:
Uri Shkolnik CEO
Haim Gil-Ad CEO
15 | P a g e
To support Personalized medicine market opportunity we’ll be happy to meet: 1. Service labs
specifically experts in Cancer Diagnostics, to develop JV’s for our test in Japan. 2. Leading
Cancer Medical and Research centers to collaborate in clinical trials. 3. Leading diagnostics
companies to collaborate in further development of the test for the Japanese market. 4.
Government agencies responsible for the Japanese Genome project. 5. Key Opinion Leaders in
Cancer medicine.
To support pharma market opportunity we’ll be happy to meet: Pharmaceutical companies
developing targeted therapy drugs.
Dr. Hillit Shachar Vice President, Business
Development [email protected]
16 | P a g e
Pluristem Therapeutics
Technology Sector: Biotechnology
Technology Subsector: Regenerative Medicine
Company Stage: Public
(Traded on NASAQ & Tel Aviv Exchange)
Website: www.pluristem.com
Company Description:
Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The
Company's cutting-edge technology produces patented PLX cells that release a cocktail of
therapeutic proteins in response to inflammation, ischemia and hematologic disorders. Diseases
linked to these conditions collectively cost the U.S. healthcare system billions of dollars. Data
from clinical studies of PLX cells demonstrate significant improvement in patients’ health. PLX
cells are off-the-shelf products, requiring no tissue matching prior to administration. Pluristem’s
key assets include: a robust pipeline of indications; unique, patented and scalable
manufacturing technology; a GMP-certified manufacturing facility; strategic partnerships with
pharmaceutical companies; a strong intellectual property position; multiple products in
development; and a seasoned management team.
Partnership Interests:
Pluristem is actively seeking potential licensing partners for its PLX product line of allogenic cell
therapies with Japanese life science companies. In addition, Pluristem is interested in working
with leading Japanese physicians and researchers in the regenerative medicine space.
Dr. Noam Emanuel Chief Technology Officer
17 | P a g e
PolyPid Ltd.
Technology Sector: Specialty Pharmaceutical
Technology Subsector: Infection focused
Company Stage: Advance Clinical stage
Website: www.polypid.com
Company Description: Polypid Ltd is an innovative Israeli company founded in 2008,
developing a proprietary drug delivery technology, PLEX™ (Polymer-Lipid Encapsulation matriX).
PLEX allows for targeted, localized drug delivery into the body over periods ranging from days
to several months while keeping the molecule drug intact, thus, providing appropriate solutions
where current local or systemic administration has limited effect, is too toxic, or both.
PLEX™ was validated in clinical settings via BonyPid-1000™, a PLEX based product that coats
bone graft substitute with antibiotics and intended for filling bone voids or defects while
supporting an antibacterial protected bone healing process. BonyPid-1000 contains a broad-
spectrum antibiotic- doxycycline, to reduce microbial colonization on the bone void filler.
BonyPid-1000 has completed a clinical trial in severe open fractures indication, demonstrating
excellent safety and efficacy results, including 0% infections in the target fracture and 0%
amputations after 6-12 months follow up (vs. average of 25% and 7% respectively in historical
control group and known literature).
Partnership Interests: Distribution - BonyPid-1000™, PolyPid is looking for a company
specialized in distributing orthopedic products to hospitals in Japan.
Partner with us to develop our research programs: (a) Anti-Inflammatory - a localized and
controlled delivery of a very small, yet effective dexamethasone dose with minimal systemic
side effects, Demonstrated safety and efficacy in a small animal model; (b) Anti-Cancer -
reducing the overall dose of toxic chemotherapeutic agents for a prolonged, local medication
while achieving effectiveness that is at least comparable to systemic administration; (c) BMP-2
Growth factor – created an effective, controlled release of proteins using
BMP-2 with excellent bone growth in rat calvarium bone defects.
R&D collaboration with Pharmaceutical
companies: Partnering with us will
provide you local drug delivery vehicle, which will
optimize your drugs’ therapeutic payload and
clinical outcome, and where applicable, will help
overcome a looming patent cliff.
Tovy Sivan CEO
18 | P a g e
STI Laser Industries
Technology Sector: Manufacturing platform for medical devices
Technology Subsector: Laser cutting, machining and welding;
Surface treatment
Company Stage: Revenue growth
Website: www.sti-laser.com
Company Description:
STI Laser Industries is a medical device contract manufacturer specializing in laser cutting,
micromachining and finishing of miniature metal components.
We focus on medical device manufacturing of implants and surgical tools used in minimally
invasive surgery and provide a comprehensive manufacturing platform for medical device, bio-
engineering and hi-tech companies seeking prototyping, small series or contract manufacturing
services.
STI is certified to EN ISO 13485 with the scope for supplying “Micro machining of metal
components, including: laser processing, heat treatment and surface treatments; Contract
manufacturing of medical implants and surgical tools, intended for minimal invasive surgery,
aesthetic surgical procedures, dental implants; Assembly and packaging of medical devices
and components in a controlled environment area.”
For more information, you are welcome to visit our website for a full understanding of our full
services and manufacturing capabilities.
Partnership Interests:
Companies in the field of medical device that are seeking for manufacturer – from startup
companies in the prototype stage to large companies that are looking for contract manufacturer
to second source.
19 | P a g e
TechsoMed
Technology Sector: Medical Devices
Technology Subsector: Medical Imaging
Company Stage: Seed
Website: www.techsomed.com
Company Description:
TechsoMed is a medical device company, developing ultrasound based real-time monitoring
systems for thermal ablation procedures. The applications of thermal ablation are numerous:
tumor destruction, heart arrhythmia, blood pressure and more. The procedure has market size
in the billions, but lacks real-time monitoring capabilities, causing high failure rates. Our one of
a kind breakthrough technology (based on two granted patents) offers added value to patients,
physicians and insurance companies by solving the high failure rate of these minimally invasive
procedures. TechsoMed’s BioTrace™ is an imaging and analysis unit, which performs 3D real
time monitoring and controlling of tissue destruction by thermal ablation devices. The system
interfaces with a standard ultrasound device enabling it to monitor and predict the progression
of tissue destruction during an ablation procedure without changing the current methodology.
Partnership Interests:
Japan represents one of the fastest growing ablation markets. The main cause is due to the
aging of Japan. One quarter of the Japanese population is aged 65 and older. Aging Japanese
population, which is at a higher risk of developing chronic diseases such as cancer and cardiac
disorders, ultimately leads to a fast growth in the ablation procedure usage. The key players in
this market are the thermal ablation and ultrasound manufacturers. We are looking to partner
with one or more of the key players (Such as Olympus medical, Hitachi medical and Toshiba
Medical) for the final stages of development and beginning of clinical testing. Our preferred go
to market strategy is to bundle our technology with an existing manufacturer's ablation/
Ultrasound device, thus capitalizing on their sales and distribution capabilities.
Yossi Abu Founder & CEO
20 | P a g e
TransAlgae Israel Ltd.
Technology Sector: Bio Technology
Technology Subsector: Agritech
Company Stage: Initial Revenues/R&D
Website: www.transalgae.com
Company Description:
TransAlgae develops an algae based platform for oral delivery of proteins based drugs and
other bio-molecules for the animal healthcare and crop protection markets.
TransAlgae’s unique technology harness algae as a cell based factory system for the production
and native encapsulation of selected bio-molecules, creating high value products. Products such
as growth promoting agents, enzymes, vaccines or other active molecules can now be orally
delivered through animal feed.
TransAlgae has a proven ability to orally deliver selected proteins to fish, shrimp and insects.
This technology can be extended to other industries such as poultry and all the way to human
pharma. Oral delivery will allow the end user to avoid the use of current inferior techniques,
such as injections.
TransAlgae’s first product is a growth promoting agent (GPA) expressing algae. Fish and
shrimps supplemented with GPA have shown significant effects of increased growth and
decreased mortality in the larval and post larval stages.
TransAlgae’s first product serves as a proof of concept for the development of future products.
Pipeline products include algae based oral vaccines targeted towards two main worldwide fish
diseases.
Additionally, based on its novel technology, TransAlgae orients itself to the field of crop
protection.
Partnership Interests:
Strategic partners, investors, R&D collaboration, distributers
www.matimop.org.il/japan.html
www.nedo.go.jp/
Gideon Zohar VP Marketing & Sales
21 | P a g e
www.nedo.go.jp/